Drug Trial Radar · NCT06833073
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
308
Planned (sponsor's estimate)
Start
Mar 11, 2025
Primary completion
Sep 3, 2031
Study completion Sep 3, 2031
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- ModernaTX, Inc.
- First posted
- Feb 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat people with high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder but has not spread to the bladder muscle or outside of the bladder. High-risk means NMIBC may have a high chance of getting worse or coming back after treatment. HR NMIBC can also include carcinoma in situ (CIS). CIS is bladder cancer that appears flat and is only in the inner layer (surface) of the bladder. CIS is not raised and is not growing toward the center of the bladder. The standard treatment for HR NMIBC is a procedure to remove the tumor called transurethral resection of the bladder tumor (TURBT) followed by Bacillus Calmette-Guerin (BCG). Standard treatment is something that is considered the first line of treatment for a condition. BCG is an immunotherapy, which is a treatment that helps the immune system fight cancer. However, BCG may not work to treat HR NMIBC in some people. Researchers want to learn if adding intismeran autogene, the study treatment, to standard treatment can help treat HR NMIBC. Intismeran autogene is designed to help a person's immune system attack their specific cancer. The goal of this study is to learn if people who receive V940 with BCG live longer and without the cancer growing, spreading, or coming back compared to people who receive BCG alone.
Conditions
- Urinary Bladder Neoplasms
- Non-Muscle Invasive Bladder Neoplasms
- Carcinoma in Situ
Interventions
Intismeran autogeneBiological
IM injection
BCGBiological
Intravesicular instillation. BCG is a preparation of Bacillus Calmette-Guerin.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort A: Event-free Survival (EFS)Time frame: Up to approximately 5 years
Locations
89 sites in 19 countries. Site status is shown where the registry gives one.
Michael G Oefelein Clinical Trials ( Site 0138)
Bakersfield, California · Recruiting
Genesis Research, LLC ( Site 0141)
Los Alamitos, California · Active not recruiting
USC Norris Comprehensive Cancer Center ( Site 0123)
Los Angeles, California · Recruiting
Genesis Healthcare-Torrance ( Site 0140)
Torrance, California · Recruiting
Genesis Research LLC ( Site 0118)
Torrance, California · Recruiting
Urology Associates ( Site 0144)
Littleton, Colorado · Recruiting
Urological Research Network ( Site 0133)
Hialeah, Florida · Recruiting
Associated Urological Specialists - Chicago Ridge ( Site 0139)
Chicago Ridge, Illinois · Recruiting
Southern Urology, LLC ( Site 0145)
Lafayette, Louisiana · Recruiting
University of Missouri Health Care ( Site 0126)
Columbia, Missouri · Recruiting
NHO Revive Research Institute, LLC ( Site 0137)
Lincoln, Nebraska · Recruiting
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0111)
New York, New York · Recruiting
TriState Urologic Services PSC Inc. dba The Urology Group ( Site 0122)
Cincinnati, Ohio · Recruiting
OHSU Knight Cancer Institute - South Waterfront ( Site 0110)
Portland, Oregon · Recruiting
MidLantic Urology ( Site 0102)
Bala-Cynwyd, Pennsylvania · Recruiting
The Conrad Pearson Clinic ( Site 0143)
Germantown, Tennessee · Recruiting
Texas Oncology-Austin Central ( Site 0107)
Austin, Texas · Recruiting
Urology Austin, PLLC ( Site 0109)
Austin, Texas · Recruiting
Urology of Virginia ( Site 0125)
Virginia Beach, Virginia · Recruiting
University of Washington - Fred Hutchinson Cancer Center ( Site 0100)
Seattle, Washington · Recruiting
Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0301)
La Rioja, Argentina · Recruiting
Hospital Italiano de Buenos Aires ( Site 0307)
CABA, Buenos Aires, Argentina · Recruiting
Instituto Alexander Fleming ( Site 0306)
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina · Recruiting
Instituto de Investigaciones Clinicas Mar de Plata ( Site 0305)
Mar del Plata, Buenos Aires, Argentina · Recruiting
Asociación de Beneficencia Hospital Sirio Libanés ( Site 0303)
Buenos Aires, Buenos Aires F.D., Argentina · Recruiting
Fundacion Estudios Clinicos ( Site 0304)
Rosario, Santa Fe Province, Argentina · Recruiting
Sanatorio Parque ( Site 0300)
Rosario, Santa Fe Province, Argentina · Recruiting
Macquarie University ( Site 1801)
Macquarie University, New South Wales, Australia · Recruiting
Fiona Stanley Hospital ( Site 1803)
Perth, Western Australia, Australia · Recruiting
Instituto do Câncer e Transplante de Curitiba ( Site 0402)
Curitiba, Paraná, Brazil · Recruiting
Hospital de Clínicas de Passo Fundo ( Site 0406)
Passo Fundo, Rio Grande do Sul, Brazil · Recruiting
Fundação Pio XII - Hospital de Câncer de Barretos ( Site 0400)
Barretos, São Paulo, Brazil · Recruiting
Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0410)
São Jose Do Rio Preto, São Paulo, Brazil · Recruiting
The Moncton Hospital-Oncology ( Site 0200)
Moncton, New Brunswick, Canada · Recruiting
Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer ( Site 0204)
Sherbrooke, Quebec, Canada · Recruiting
Bradford Hill Norte ( Site 0503)
Antofagasta, Chile · Recruiting
Oncocentro Valdivia ( Site 0507)
Valdivia, Los Ríos Region, Chile · Recruiting
Fundación Arturo López Pérez ( Site 0500)
Santiago, Region M. de Santiago, Chile · Recruiting
Pontificia Universidad Catolica de Chile ( Site 0502)
Santiago, Region M. de Santiago, Chile · Recruiting
Bradfordhill ( Site 0501)
Santiago, Region M. de Santiago, Chile · Recruiting
Showing 40 of 89 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.